Adagene's Muzastotug Shows 31% ORR in MSS CRC, Cash Runway Extended to Late 2028
ADAG has more than doubled off its 52-week low of $1.3.
Summary
Adagene reported H1 2026 results with $127.9M in cash, extending runway into late 2028. The lead asset muzastotug demonstrated a 31% confirmed ORR in MSS CRC at the 20 mg/kg dose, with median PFS of 6.7 months and OS not yet reached. A randomized Phase 2 trial is enrolling, with results expected in 1H 2027, and a potential registration trial could start in 2027. Dosing has begun in a global Phase 1/2 basket trial with a Sanofi next-gen IO agent. The data strengthens muzastotug's profile as a backbone therapy, and the cash position supports pipeline acceleration.
At the time of this announcement, ADAG was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.3M. The 52-week trading range was $1.30 to $4.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.